AI assistant
PDS Biotechnology Corp — Director's Dealing 2025
Jul 26, 2025
34613_dirs_2025-07-25_a11798d3-f822-4035-aa2d-87e2bee05e8e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PDS Biotechnology Corp (PDSB)
CIK: 0001472091
Period of Report: 2024-02-28
Reporting Person: Brown Spencer D. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-28 | Employee Stock Option (Right to Buy) | $5.87 | A | 56000 | Acquired | 2034-02-28 | Common Stock (56000) | Direct |
| 2025-06-12 | Employee Stock Option (Right to Buy) | $1.79 | A | 150000 | Acquired | 2035-06-12 | Common Stock (150000) | Direct |
Footnotes
F1: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on February 28,2025, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
F2: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on June 12, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.